DBV Technologies reported $8.59M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 52.19M 2.62M Dec/2025
Alnylam Pharmaceuticals USD 1.28B 30.06M Dec/2025
Amarin USD 0 0 Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
DBV Technologies USD 8.59M 295K Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 39.43M 982K Mar/2026
Insmed USD 727.62M 275K Mar/2026
Ionis Pharmaceuticals USD 2.34B 9.5M Mar/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025